Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Subcutaneous CT-P13 in Rheumatoid Arthritis
2024-510945-32-00Phase 3Completed
- Sponsor
- Celltrion
- Start
- Dec 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of infliximab in rheumatoid arthritis (RA) (2 arms), sponsored by Celltrion. Primary endpoint: ACR20 response at Week 12. Started Dec 2024; status: completed.
02
Drugs
infliximab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2024-510945-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510945-32-00.